Corium Innovations to highlight patented Transdermal and Oral Thin Film drug delivery technologies at DCAT week

Grand Rapids, Michigan, March 4, 2025 – Corium Innovations, Inc. , a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, announced today that it will be featuring its industry leading transdermal and oral thin film technologies at Drug, Chemical & Associated Technologies Association (DCAT) Week, the premier global bio/pharmaceutical manufacturing value chain meeting, to be held March 17-20 in New York City.

With 25 years of making and leveraging groundbreaking transdermal delivery systems since it was founded, and 90 patents, Corium Innovations maintains fully integrated research & development capabilities along with annual manufacturing capacity of more than 200 million transdermal patches/films at its 200,000 square foot GMP facility in Grand Rapids, Michigan. Corium Innovations brings the best of its proprietary transdermal and transmucosal delivery platforms to different patient and consumer groups in customary or challenging usage situations.

"Our relentless pursuit of innovation in drug delivery allows us to go beyond just providing medication. We strive to enhance overall health outcomes," said Dr. Mark Sirgo, Chief Executive Officer at Corium Innovations. "Our dedicated teams of scientists and engineers are constantly discovering new ways to tailor our adaptable technologies for a wide array of therapies. We are committed to developing high-value brands and complex generic products, both for our current partners and those we will collaborate with in the future."

Corium Innovations’ proprietary Corplex® transdermal innovation platform breaks new ground in drug delivery with a proprietary mix of adhesives, polymers and liners that can be adjusted for almost any use situation. From teeth whitening strips, to the first and only 7-day low-dose estrogen birth control patch, Corplex is helping millions of people get the help and benefits they are seeking in a way that works better for their lives.

About Corium Innovations

Headquartered in Grand Rapids, Michigan, Corium Innovations is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Innovations offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and its proprietary proven drug delivery technology Corplex®. For more information, visit www.coriuminv.com.

About Gurnet Point Capital

Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. For more information, visit www.gurnetpointcapital.com.

About Webster Equity Partners

Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. For more information, visit www.websterequitypartners.com.

Contact

Gartman PR
gartmanpr@gmail.com
202-413-4226